174 related articles for article (PubMed ID: 20361800)
1. 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity.
Choi SJ; Lee JE; Jeong SY; Im I; Lee SD; Lee EJ; Lee SK; Kwon SM; Ahn SG; Yoon JH; Han SY; Kim JI; Kim YC
J Med Chem; 2010 May; 53(9):3696-706. PubMed ID: 20361800
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, biological evaluation, and molecular docking studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline derivatives as novel anticancer agents.
Huang XF; Lu X; Zhang Y; Song GQ; He QL; Li QS; Yang XH; Wei Y; Zhu HL
Bioorg Med Chem; 2012 Aug; 20(16):4895-900. PubMed ID: 22819191
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities.
Moon MJ; Lee SK; Lee JW; Song WK; Kim SW; Kim JI; Cho C; Choi SJ; Kim YC
Bioorg Med Chem; 2006 Jan; 14(1):237-46. PubMed ID: 16182537
[TBL] [Abstract][Full Text] [Related]
4. 3-Hydroxychromones as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.
Lee J; Park T; Jeong S; Kim KH; Hong C
Bioorg Med Chem Lett; 2007 Mar; 17(5):1284-7. PubMed ID: 17178224
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel indirubin-3'-monoxime derivatives as potent inhibitors against CDK2 and CDK9.
Yan L; Lai F; Chen X; Xiao Z
Bioorg Med Chem Lett; 2015 Jun; 25(11):2447-51. PubMed ID: 25908517
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore.
Kritsanida M; Magiatis P; Skaltsounis AL; Peng Y; Li P; Wennogle LP
J Nat Prod; 2009 Dec; 72(12):2199-202. PubMed ID: 19994845
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
Ibrahim DA; Ismail NS
Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
[TBL] [Abstract][Full Text] [Related]
8. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
Elgazwy AS; Ismail NS; Elzahabi HS
Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.
Ibrahim DA; El-Metwally AM
Eur J Med Chem; 2010 Mar; 45(3):1158-66. PubMed ID: 20045222
[TBL] [Abstract][Full Text] [Related]
10. Indirubin-3-monooxime induced cell cycle arrest and apoptosis in Hep-2 human laryngeal carcinoma cells.
Kameswaran TR; Ramanibai R
Biomed Pharmacother; 2009 Feb; 63(2):146-54. PubMed ID: 18450412
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of noble indirubin derivatives in human solid tumor models in vitro.
Kim SH; Choi SJ; Kim YC; Kuh HJ
Arch Pharm Res; 2009 Jun; 32(6):915-22. PubMed ID: 19557370
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors.
Lee J; Kim KH; Jeong S
Bioorg Med Chem Lett; 2011 Jul; 21(14):4203-5. PubMed ID: 21684737
[TBL] [Abstract][Full Text] [Related]
13. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity.
Schultz C; Link A; Leost M; Zaharevitz DW; Gussio R; Sausville EA; Meijer L; Kunick C
J Med Chem; 1999 Jul; 42(15):2909-19. PubMed ID: 10425100
[TBL] [Abstract][Full Text] [Related]
14. Imidazole-4,5-dicarboxamide derivatives with antiproliferative activity against HL-60 cells.
Perchellet EM; Perchellet JP; Baures PW
J Med Chem; 2005 Sep; 48(19):5955-65. PubMed ID: 16161999
[TBL] [Abstract][Full Text] [Related]
15. 7-Bromoindirubin-3'-oxime induces caspase-independent cell death.
Ribas J; Bettayeb K; Ferandin Y; Knockaert M; Garrofé-Ochoa X; Totzke F; Schächtele C; Mester J; Polychronopoulos P; Magiatis P; Skaltsounis AL; Boix J; Meijer L
Oncogene; 2006 Oct; 25(47):6304-18. PubMed ID: 16702956
[TBL] [Abstract][Full Text] [Related]
16. Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.
Braña MF; Cacho M; García ML; Mayoral EP; López B; de Pascual-Teresa B; Ramos A; Acero N; Llinares F; Muñoz-Mingarro D; Lozach O; Meijer L
J Med Chem; 2005 Nov; 48(22):6843-54. PubMed ID: 16250643
[TBL] [Abstract][Full Text] [Related]
17. Semi-empirical calculations on paullones, a promising class of cyclin-dependent kinase inhibitors.
Sharma PS; Tyagi R; Sharma R
Indian J Biochem Biophys; 2008 Dec; 45(6):416-20. PubMed ID: 19239129
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel pyrimidine-based benzothiazole derivatives as potent cyclin-dependent kinase 2 inhibitors with anticancer activity.
Diao PC; Lin WY; Jian XE; Li YH; You WW; Zhao PL
Eur J Med Chem; 2019 Oct; 179():196-207. PubMed ID: 31254921
[TBL] [Abstract][Full Text] [Related]
19. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ
Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
Wee XK; Yeo WK; Zhang B; Tan VB; Lim KM; Tay TE; Go ML
Bioorg Med Chem; 2009 Nov; 17(21):7562-71. PubMed ID: 19783149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
